Thursday, March 07, 2024 9:03:07 AM
MindMed’s stock jumps 24% after FDA grants breakthrough designation to LSD therapy for a form of anxiety
By Ciara LinnaneFollow
Biotech also issues new shares and reports positive data from Phase 2b trial
Mind Medicine Inc.’s stock jumped 24% early Thursday, after the biotech company said the Food and Drug Administration has granted breakthrough designation for its MM120 LSD-based treatment for generalized anxiety disorder.
Published: March 7, 2024 at 8:26 a.m. ET
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM